CAPR Stock Overview A clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Capricor Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Capricor Therapeutics Historical stock prices Current Share Price US$13.07 52 Week High US$23.40 52 Week Low US$3.52 Beta 4.03 1 Month Change -30.92% 3 Month Change 158.81% 1 Year Change 193.71% 3 Year Change 285.55% 5 Year Change 1,026.72% Change since IPO -68.88%
Recent News & Updates See more updates
Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding Dec 12
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission Dec 06
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 14
Capricor Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 05
New major risk - Shareholder dilution Oct 20 Capricor Therapeutics, Inc. Intends to File A Biologics License Application Capricor Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $75.004 million.
Capricor Therapeutics Announces Positive Long-Term Data from Hope-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress Oct 12
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy Oct 09
Price target increased by 28% to US$25.40 Sep 24
Forecast to breakeven in 2026 Sep 24
New minor risk - Share price stability Sep 24
Consensus revenue estimates increase by 21% Sep 19
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28% Sep 18 Capricor Therapeutics, Inc. announced that it has received $14.999998 million in funding from Nippon Shinyaku Co., Ltd. Sep 18
Consensus revenue estimates fall by 16% Aug 15
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 08
Capricor Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 31
Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel Jul 30
New major risk - Financial position Jul 01
Capricor Therapeutics, Inc. Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy Jun 29
Capricor Therapeutics, Inc. Announces for the Treatment of Duchenne Muscular Dystrophy Jun 25
New minor risk - Profitability Jun 07
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from Hope-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Jun 05
Consensus revenue estimates increase by 24%, EPS downgraded May 20
Forecast breakeven date pushed back to 2026 May 17
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 14
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting May 10
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up May 08
Capricor Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024 May 08
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy Apr 24
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet Apr 19
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate Apr 16
Capricor Therapeutics, Inc., Annual General Meeting, May 14, 2024 Apr 02
Consensus revenue estimates increase by 41% Mar 18
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference Mar 07
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 03
Capricor Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 23
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues Feb 03
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2 Jan 24
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth? Dec 13
Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis Dec 12
New major risk - Financial position Nov 19
Capricor Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 08
Consensus revenue estimates fall by 51% Oct 04
New minor risk - Market cap size Oct 03
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy Oct 01
Capricor Therapeutics, Inc. Appoints Michael Kelliher to Its Board of Directors Sep 07
New minor risk - Share price stability Aug 22
Consensus revenue estimates increase by 86% Aug 15
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation Aug 13
Forecast breakeven date moved forward to 2024 Aug 08
Capricor Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Aug 03
Insufficient new directors Aug 01 Capricor Therapeutics Announces the Appointment of Philip J. Gotwals to Its Board of Directors
Capricor Therapeutics, Inc Announces Board Changes Jul 14
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Jul 01
Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Jun 08
Consensus revenue estimates increase by 27% May 18
Forecast breakeven date moved forward to 2024 May 14
Capricor Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Chief Business Officer exercised options and sold US$51k worth of stock Apr 09
Independent Director notifies of intention to sell stock Mar 27
Forecast breakeven date moved forward to 2024 Mar 17
Capricor Therapeutics, Inc. Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients Jan 26
Forecast to breakeven in 2025 Dec 31
Now 26% undervalued after recent price drop Dec 05
Consensus revenue estimates increase by 146% Nov 17
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 16
Insufficient new directors Nov 16
Forecast to breakeven in 2024 Nov 12
Now 20% undervalued after recent price drop Nov 12
Capricor Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR) Nov 03
Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03 Aug 10
Capricor Therapeutics, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Aug 04
Capricor Therapeutics, Inc. Announces First Patient Dose in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Jul 20
Independent Director recently sold US$79k worth of stock Jul 01
Capricor Therapeutics, Inc. Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with Cap-1002 in Hope-2 Open Label Extension Study Jun 28
Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer May 26
Forecast to breakeven in 2023 May 12
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 11
Capricor Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022 May 04
Price target increased to US$15.00 Apr 27
Insufficient new directors Apr 27
Capricor Therapeutics, Inc., Annual General Meeting, Jun 03, 2022 Apr 14
Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory Inspire Trial in Severe Hospitalized Covid-19 Patients Mar 29 Shareholder Returns CAPR US Biotechs US Market 7D -1.4% -5.6% -3.5% 1Y 193.7% -1.5% 22.1%
See full shareholder returns
Return vs Market: CAPR exceeded the US Market which returned 22.1% over the past year.
Price Volatility Is CAPR's price volatile compared to industry and market? CAPR volatility CAPR Average Weekly Movement 27.0% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CAPR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CAPR's weekly volatility has increased from 16% to 27% over the past year.
About the Company Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
Show more Capricor Therapeutics, Inc. Fundamentals Summary How do Capricor Therapeutics's earnings and revenue compare to its market cap? CAPR fundamental statistics Market cap US$586.56m Earnings (TTM ) -US$34.11m Revenue (TTM ) US$23.23m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CAPR income statement (TTM ) Revenue US$23.23m Cost of Revenue US$45.35m Gross Profit -US$22.13m Other Expenses US$11.99m Earnings -US$34.11m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.75 Gross Margin -95.25% Net Profit Margin -146.86% Debt/Equity Ratio 0%
How did CAPR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 22:38 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Capricor Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kristen Kluska Cantor Fitzgerald & Co. Reni Benjamin H.C. Wainwright & Co. Joseph Pantginis H.C. Wainwright & Co.
Show 7 more analysts 
